Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a large-scale stepped-wedge implementation of Project ECHO Diabetes demonstrated substantial HbA1c improvement and cost savings; a PRISMA-compliant systematic review clarified how ketogenic diets modulate gonadal hormones, with signals of benefit in PCOS; and a global pharmacovigilance analysis flagged heterogeneity and specific psychiatric safety signals for semaglutide among GLP-1 receptor agonists.
Summary
Three impactful endocrinology papers stand out today: a large-scale stepped-wedge implementation of Project ECHO Diabetes demonstrated substantial HbA1c improvement and cost savings; a PRISMA-compliant systematic review clarified how ketogenic diets modulate gonadal hormones, with signals of benefit in PCOS; and a global pharmacovigilance analysis flagged heterogeneity and specific psychiatric safety signals for semaglutide among GLP-1 receptor agonists.
Research Themes
- Implementation science in diabetes care and health economics
- Dietary interventions and endocrine hormone regulation
- Post-marketing safety of incretin-based therapies
Selected Articles
1. Evaluating the Economic Impact of Project ECHO Diabetes: Cost Savings From HbA1c Reduction in Type 1 and Type 2 Diabetes.
In a stepped-wedge implementation across FQHCs, Project ECHO Diabetes reduced the proportion of patients with HbA1c >9% in both type 1 and type 2 diabetes and generated first-year cost savings exceeding $5 million versus program costs. These findings support scaling tele-education to improve glycemic control and reduce expenditures in underserved settings.
Impact: This large real-world implementation links HbA1c improvement to substantial, quantifiable cost savings, informing health system and policy decisions.
Clinical Implications: Health systems can deploy tele-education models like ECHO to reduce high HbA1c prevalence and realize near-term cost offsets, particularly in underserved primary care settings.
Key Findings
- Across 32,796 adults, HbA1c >9% fell from 31.7% to 26.7% in type 1 diabetes and 24.0% to 18.9% in type 2 diabetes after a 6-month intervention.
- Estimated first-year per-patient savings were $3,205.95, with total savings exceeding $5 million versus $513,257 program costs.
- Intervention components included bimonthly tele-education, real-time specialist support, and access to diabetes management resources.
Methodological Strengths
- Stepped-wedge implementation across multiple FQHC sites with a very large sample size
- Use of established literature-based cost models adjusted to 2023 USD
Limitations
- Non-randomized implementation; potential secular trends and unmeasured confounding
- Cost savings estimated from literature rather than measured claims utilization
Future Directions: Randomized or controlled stepped-wedge trials with claims-based cost validation and longer follow-up to assess durability, equity impacts, and scalability.
OBJECTIVE: Elevated HbA1c levels (>9%) increase the risk of complications and drive higher health care costs, particularly in communities with limited access to specialty care. Project ECHO Diabetes offers a scalable tele-education model to empower primary care providers in delivering effective diabetes management. This study assessed the economic impact of Project ECHO Diabetes by estimating health care cost savings from reductions in HbA1c levels >9% and comparing these savings against program costs. METHODS: A stepped-wedge design was used to implement Project ECHO Diabetes across Federally Qualified Health Centers in California and Florida between 2021 and 2022. Data were collected before and after the 6-month intervention to assess HbA1c changes, with health care cost savings estimated using established literature and adjusted to 2023 USD. RESULTS: The study included 32 796 adults with type 1 diabetes (n = 1127) or type 2 diabetes (n = 31 669). The intervention consisted of bimonthly tele-education sessions, real-time medical support, and access to diabetes management resources over 6 months. The primary outcome was health care cost savings derived from HbA1c reductions >9% and comparison with program costs. The proportion of patients with HbA1c >9% decreased from 31.7% to 26.7% for type 1 diabetes and 24.0% to 18.9% for type 2 diabetes. Estimated first-year per-patient savings were $3205.95, with total program savings exceeding $5 million, far outweighing implementation costs of $513,257. CONCLUSIONS: Project ECHO Diabetes achieved substantial cost savings through improved glycemic control, supporting its broader implementation to enhance diabetes care and reduce health care costs.
2. Effects of the Ketogenic Diet on Gonadal Hormones: A Systematic Review.
This PRISMA-compliant systematic review (7 studies, 4–24 weeks) shows that eucaloric, normoproteic ketogenic diets modulate gonadal hormones. Benefits include decreased testosterone and improved LH/FSH ratio and insulin sensitivity in women with PCOS, and context-dependent changes in total testosterone and IGF-1 in active men.
Impact: Clarifies endocrine effects of ketogenic diets with implications for PCOS management and athlete health, consolidating human data under rigorous review standards.
Clinical Implications: Clinicians may consider a monitored ketogenic diet as an adjunct for PCOS to improve hyperandrogenism and cycle regularity, while tailoring strategies in active men given potential anabolic hormone shifts.
Key Findings
- Seven human studies (4–24 weeks) were included; three in women and four in active/athletic men.
- Women with PCOS showed decreased testosterone, improved LH/FSH ratio, better insulin sensitivity, and improved menstrual regularity on ketogenic diets.
- Active men exhibited context-dependent changes in total testosterone and IGF-1 influenced by exercise intensity, baseline fat-free mass, and caloric intake.
- Most studies reported oscillations in multiple gonadal hormones (testosterone, LH, FSH, estradiol, progesterone, DHEA).
Methodological Strengths
- PRISMA-reported, Cochrane Handbook–guided systematic review
- PROSPERO-registered protocol with focus on human studies
Limitations
- Small number of studies with heterogeneity in populations and exercise contexts
- No meta-analysis and limited long-term outcomes
Future Directions: Large, pre-registered RCTs stratified by PCOS status, activity level, and caloric targets to define endocrine and clinical endpoints, with long-term safety monitoring.
CONTEXT: Ketogenic diets (KDs) are a set of medical nutritional therapies in which macronutrient consumption is consistently high in fat, adequate in protein, and low in carbohydrates. They have been shown to be clinically useful in a myriad of medical conditions. OBJECTIVE: The aim of this study was to systematically review the literature aiming to evaluate the effects of a eucaloric, normoproteic, ketogenic diet (KD) on gonadal hormone levels in adults. DATA SOURCES: The PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and Science Direct (via Scopus) databases were searched for relevant articles in November 2021, and the search was updated in December 2023. DATA EXTRACTION: The present systematic review was conducted according to the 6th version of the Cochrane Handbook for Systematic Reviews of Interventions and is reported according to PRISMA. This review only included studies with humans, such as randomized clinical trials, cohort studies, and cross-sectional studies. Levels of gonadal hormones were considered the primary outcome. DATA ANALYSIS: A total of 7 articles were included in the review: 3 studies were conducted with female participants only, and 4 with active or athletic males. The duration of the intervention was a minimum of 4 weeks and a maximum of 24 weeks. Most studies found oscillation of gonadal hormones, (such as total testosterone, luteinizing hormone [LH], follicle-stimulating hormone [FSH], estradiol, progesterone, and dehydroepiandrosterone) as an effect of the dietary intervention. CONCLUSION: A eucaloric isonitrogenous KD may offer (i) beneficial weight loss, (ii) a change in anabolic hormone levels (total testosterone, insulin-like growth factor 1 [IGF-1] in physically active men, depending on the intensity of exercise, the amount of fat-free mass when starting the diet, and the caloric volume of the diet), and a beneficial effect on gonadal hormones in women with polycystic ovary syndrome (by decreasing testosterone levels, improving the LH/FSH ratio, improving insulin sensitivity, and improving menstrual cycle regularity. Factors such as the study population, the presence of comorbidities, and the physical activity level of the participants may influence these effects. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42021256766.
3. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
Global pharmacovigilance data showed increased reporting of depressed mood and suicidality with semaglutide and strong signals for eating disorders across GLP-1 RAs, despite no overall rise in psychiatric ADRs. Heterogeneity analyses highlight regional and demographic differences, supporting vigilance and risk-tailored monitoring.
Impact: Identifies specific psychiatric safety signals for widely used incretin therapies using advanced causal forest methods, informing clinical monitoring and regulatory review.
Clinical Implications: Screen for depressive symptoms and suicidality, particularly in patients with obesity on semaglutide for weight management; counsel about eating behavior changes across GLP-1 RAs and consider shared decision-making.
Key Findings
- Among 2,061,901 reports, 21,414 psychiatric ADRs involved GLP-1 RAs.
- Semaglutide showed elevated aRORs for anxiety (1.26), depressed mood disorders (1.70), and suicidality (1.45).
- Eating disorder signals were strong across dulaglutide, semaglutide, and liraglutide (aROR 4.17–6.80).
- Causal forest estimated an average treatment effect of 0.0046 for semaglutide on depression/suicidality reporting, with significant regional heterogeneity.
Methodological Strengths
- Use of a large, multinational pharmacovigilance database (VigiBase) with adjusted disproportionality analyses
- Application of causal forest modeling to explore heterogeneity in safety signals
Limitations
- Spontaneous reporting subject to underreporting, reporting biases, and lack of exposure denominators
- Causality cannot be inferred; confounding by indication and regional reporting practices may influence findings
Future Directions: Linkage studies combining pharmacovigilance with prescription/exposure data and prospective cohorts to clarify causality and identify at-risk subgroups.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are crucial in managing type 2 diabetes mellitus (T2DM) and obesity. Agents like dulaglutide, semaglutide, and liraglutide mimic endogenous GLP-1, enhancing insulin secretion and promoting satiety. Beyond glycemic control, they offer cardioprotective and neuroprotective benefits. However, concerns about psychiatric adverse effects have emerged, necessitating a systematic assessment of their safety profile. MATERIAL & METHODS: This multinational pharmacovigilance study utilized VigiBase® data up to December 1, 2024, focusing on adverse drug reaction (ADR) reports for GLP-1 RAs. Psychiatric ADRs were classified using MedDRA terminology. Disproportionality analyses were conducted via logistic regression to calculate reporting adjusted Reporting Odds Ratios (aRORs) within reports involving antidiabetic or anti-obesity medications. A causal forest model assessed the individual treatment effect (ITE) of semaglutide on depression and suicidality reporting. RESULTS: Among 2,061,901 reports, 21,414 involved psychiatric ADRs for GLP-1 RAs. Significant signals were observed for anxiety (aROR: 1.26, 95%CI: 1.18-1.35), depressed mood disorders (aROR: 1.70, 95%CI: 1.57-1.84) and suicidality (aROR 1.45, 95%CI: 1.29-1.63) with semaglutide, and eating disorders with all three GLP-1 RAs (aRORs between 4.17 and 6.80). The causal forest model estimated an average treatment effect of 0.0046 for semaglutide on depression and suicidality reporting, with significant heterogeneity across regions and demographic groups. DISCUSSION: The study found no significant increase in overall psychiatric ADR reporting for GLP-1 RAs, except for eating disorders and depression/suicidality in semaglutide-treated patients. Sensitivity analyses before June 4, 2021, found no signals, aligning with RCT data. Post-marketing reports linked semaglutide to depression and suicidal ideation, prompting regulatory investigations. The causal forest model revealed significant heterogeneity in the psychiatric safety profile of semaglutide, with regional factors influencing ADR reporting. CONCLUSION: While GLP-1 RAs do not show a significant increase in overall psychiatric ADR reporting, findings suggest that clinicians should remain vigilant for potential depressive symptoms and suicidality, particularly in individuals with obesity treated with semaglutide since its approval for weight management.